|
| Friday, July 20, 2012 |
|
|
Horizon Pharma Moving Ahead of FDA Decision |
| Shares of the pain drug developer Horizon Pharma (NASDAQ:HZNP) have recently seen some huge moves to the upside as the FDA's decision looms for the company's rheumatoid arthritis treatment RAYOS gets closer. Even after a virtual doubling of the shares since June, the company is valued at modest $265 million. more info >> |
|
| Thursday, July 19, 2012 |
|
|
Trade Catalyst: Verisante Readies Commercial Launch of Innovative Skin Cancer Detection Platform |
| There is a growing epidemic of skin cancer and one emerging medical device firm is poised to capture a big market position and visibility as they prepare to launch a device which addresses this growing need. more info >> |
|
|
Verisante Readies Commercial Launch of Innovative Skin Cancer Detection Platform |
| There is a growing epidemic of skin cancer and one emerging medical device firm is poised to capture a big market position and visibility as they prepare to launch a device which addresses this growing need. more info >> |
|
|
Verisante Readies Commercial Launch of Revolutionary Platform To Fight Skin Cancer Epidemic |
| There is an epidemic of skin cancer and one emerging medical device firm is poised to capture a big market position and visibility as they prepare to launch a device which addresses this growing need. more info >> |
|
| Wednesday, July 18, 2012 |
|
|
Q&A: How real is the threat of a global pandemic involving H5N1 or a related virus? |
| Andy Sheldon is the CEO of Medicago Inc. (TSX: MDG) (OTCQX: MDCGF) (PINK:MDCGF). more info >> |
|
|
Trovagene May Have Solved the Elusive Liquid Biopsy |
| For several decades, researches have been developing technology that will pinpoint cancer cells or DNA fragments (nucleic acids) in blood to detect cancer in patients. Several factors have held this technology back; one the most difficult hurdles is the need for large amount of blood samples. more info >> |
|
| Thursday, July 5, 2012 |
|
|
Obagi: Over-Hyped Aquisition Target or Worthy Investment? |
| There has been abundant buzz on a company whose shares have been rising steadily since February. Obagi Medical Products (NASDAQ:OMPI) saw shares hit $16.03 last week as speculators took positions ahead of the latest round of buy-out chatter. more info >> |
|
| Monday, July 2, 2012 |
|
|
After the Big Victory for Arena, What Next? |
| Arena Pharmaceuticals (NASDAQ:ARNA) made history last week, pushing through the first new diet drug in 13 years, with the Food and Drug Administration's approval of Lorcaserin. more info >> |
|
| Saturday, June 30, 2012 |
|
|
Street Buzzing about New Hepatitis Treatment Developer |
| Despite a terrible day for the general markets on Thursday, shares of Medgenics Inc. (AMEX:MDGN) closed strong at $11.00 +1.01, +10.11% on rumors of positive developments ahead. more info >> |
|
|
Antares Focusing on Top Line Growth |
| Antares Pharma (NASDAQ:ATRS) focuses on self-injection pharmaceutical products and technologies and topical gel-based products. more info >> |
|
|
|
|
